Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Viral Genetics to develop drug therapies for immune-related disorders and diseases

The University of Colorado and Viral Genetics Inc., recently executed an exclusive license agreement that expands on its previous agreement allowing Viral Genetics to develop treatments for autoimmune diseases, graft rejection, HIV, and cancer based on the work of M. Karen Newell, Ph.D., a professor of biology at the University of Colorado at Colorado Springs.

4 Dec 2009

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Alkermes, Inc. and Acceleron Pharma, Inc. today announced that Alkermes has licensed a proprietary long-acting Fc fusion technology platform, called the Medifusion™ technology, which is designed to extend the circulating half-life of proteins and peptides.

4 Dec 2009

Galapagos' multiple milestone achievement triggers cash payment of EUR 10.2 million

Galapagos NV announced today achievement of multiple milestones under its alliance agreement in rheumatoid arthritis. The milestones trigger a cash payment of EUR 10.2 million to Galapagos.

3 Dec 2009

Lunasin may have important health benefits, two new studies report

Two new University of Illinois studies report that lunasin, a soy peptide often discarded in the waste streams of soy-processing plants, may have important health benefits that include fighting leukemia and blocking the inflammation that accompanies such chronic health conditions as diabetes, heart disease, and stroke.

3 Dec 2009

Burrill Biotech Select Index manages to claw back almost half the value it lost in October

The Burrill Biotech Select Index managed to claw back almost half the value it lost in October. The Select's gain of 4.5 percent mirrored what was also an excellent month for the general markets with the Dow up 6.5 percent and the NASDAQ up 4.8 percent in value.

2 Dec 2009

DiaMedica to acquire all issued and outstanding shares of Sanomune

DiaMedica Inc. (TSX VENTURE:DMA)("Diamedica"), a biopharmaceutical company that has discovered and is developing a novel approach to treating diabetes, announces it has entered into a non-binding letter of intent to acquire all of the issued and outstanding shares of Sanomune Inc.

2 Dec 2009

Amgen to present updated data on Nplate at the 2009 ASH meeting

Amgen Inc. today announced that it will present updated long-term safety and efficacy data for Nplate® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Additionally, Amgen will present the first Nplate study in a pediatric setting as well as in patients with myelodysplastic syndromes (MDS) at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition (Dec. 5 - 8, 2009).

1 Dec 2009

Article on TYSABRI for treating patients with multiple sclerosis published

Best-practice recommendations for the selection and management of patients with multiple sclerosis (MS) who may benefit from, or are receiving treatment with TYSABRI- (natalizumab) were published today in a supplement to the medical journal Multiple Sclerosis.

1 Dec 2009

European Patent Office grants patent EP1392642 for 4SC AG's lead auto-immune compound

4SC AG, a drug discovery and development company, today announced that the European Patent Office has granted patent EP1392642, which covers its lead auto-immune compound 4SC-101.

1 Dec 2009

CCII capsules offer safe and effective treatment for rheumatoid arthritis

Chicken collagen can provide relief from rheumatoid arthritis (RA) symptoms. A randomised, controlled trial, published in BioMed Central's open access journal Arthritis Research & Therapy, has found that Chicken type II collagen (CCII), a protein extracted from the cartilage of chicken breast, is a safe and effective treatment for RA.

1 Dec 2009

OSEO awards fund for Galapagos NV's antibody therapeutics program

Galapagos NV announces that its antibody therapeutics program with MorphoSys and SARM program have been awarded funding by the French governmental organization OSEO.

26 Nov 2009

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

ChemoCentryx, Inc., announced today that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease demonstrated clinical efficacy with a favorable safety and tolerability profile. The

25 Nov 2009

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

Ohr Pharmaceutical Inc. is developing OHR/AVR118 for treatment of cachexia based on technology acquired earlier this year from Advanced Viral Research Corp. OHR/AVR118 has shown excellent therapeutic efficacy and safety in human clinical trials in over 100 patients with applications for cachexia in Cancer and AIDS patients, as well as Rheumatoid Arthritis.

24 Nov 2009

Vitamin D: A multi-purpose nutrient for overall health

A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic."

24 Nov 2009

NAPRELAN Dose Card launched by Victory Pharma

Victory Pharma, Inc. ("Victory") announced today the launch of NAPRELAN® Dose Card, a further extension of Victory's NAPRELAN franchise.

23 Nov 2009

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Ligand Pharmaceuticals Incorporated today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of male hypogonadism and postmenopausal osteoporosis.

20 Nov 2009

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

Ligand Pharmaceuticals Incorporated announced today that it has received $2 million in milestone payments from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that is due to expire at the end of December.

19 Nov 2009

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).

19 Nov 2009

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.

19 Nov 2009

Johns Hopkins University to create a Human Proteome Chip using Arrayit's technology

Arrayit Corporation announced today that the new High Throughput Biology Center at Johns Hopkins University School of Medicine in Baltimore Maryland purchased Arrayit's proprietary technology to create a Human Proteome Chip to discover biomarkers for autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis (first identified by Dr. Zhu), lupus, and others.

18 Nov 2009

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Viral Genetics to develop drug therapies for immune-related disorders and diseases

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Galapagos' multiple milestone achievement triggers cash payment of EUR 10.2 million

Lunasin may have important health benefits, two new studies report

Burrill Biotech Select Index manages to claw back almost half the value it lost in October

DiaMedica to acquire all issued and outstanding shares of Sanomune

Amgen to present updated data on Nplate at the 2009 ASH meeting

Article on TYSABRI for treating patients with multiple sclerosis published

European Patent Office grants patent EP1392642 for 4SC AG's lead auto-immune compound

CCII capsules offer safe and effective treatment for rheumatoid arthritis

OSEO awards fund for Galapagos NV's antibody therapeutics program

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

Vitamin D: A multi-purpose nutrient for overall health

NAPRELAN Dose Card launched by Victory Pharma

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Johns Hopkins University to create a Human Proteome Chip using Arrayit's technology

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in